| 000 | 02678 a2200697 4500 | ||
|---|---|---|---|
| 005 | 20250516102123.0 | ||
| 264 | 0 | _c20121123 | |
| 008 | 201211s 0 0 eng d | ||
| 022 | _a1941-7705 | ||
| 024 | 7 |
_a10.1161/CIRCOUTCOMES.111.963637 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYusuf, Salim | |
| 245 | 0 | 0 |
_aComparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. _h[electronic resource] |
| 260 |
_bCirculation. Cardiovascular quality and outcomes _cJul 2012 |
||
| 300 |
_a463-71 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAspirin _xadministration & dosage |
| 650 | 0 | 4 |
_aAtenolol _xadministration & dosage |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 | _aCapsules |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xetiology |
| 650 | 0 | 4 |
_aCholesterol, LDL _xblood |
| 650 | 0 | 4 |
_aCreatinine _xblood |
| 650 | 0 | 4 |
_aDietary Supplements _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Rate _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrochlorothiazide _xadministration & dosage |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aHypercholesterolemia _xcomplications |
| 650 | 0 | 4 |
_aHypertension _xcomplications |
| 650 | 0 | 4 | _aIndia |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aPolypharmacy |
| 650 | 0 | 4 |
_aPotassium _xadministration & dosage |
| 650 | 0 | 4 |
_aRamipril _xadministration & dosage |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSimvastatin _xadministration & dosage |
| 650 | 0 | 4 | _aTablets |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aPais, Prem | |
| 700 | 1 | _aSigamani, Alben | |
| 700 | 1 | _aXavier, Denis | |
| 700 | 1 | _aAfzal, Rizwan | |
| 700 | 1 | _aGao, Peggy | |
| 700 | 1 | _aTeo, Koon K | |
| 773 | 0 |
_tCirculation. Cardiovascular quality and outcomes _gvol. 5 _gno. 4 _gp. 463-71 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/CIRCOUTCOMES.111.963637 _zAvailable from publisher's website |
| 999 |
_c21937741 _d21937741 |
||